Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The varicella vaccine is a live attenuated biologic agent designed to induce active immunity against the varicella-zoster virus (VZV), the causative agent of chickenpox. In the context of a Phase 4 clinical trial led by the Hospital Clinic of Barcelona, this commercial vaccine was evaluated as part of a broader immunization schedule for HIV-infected adults who had achieved undetectable viral loads through highly active antiretroviral therapy (HAART). The study's primary objective was to investigate the safety and immunomodulatory effects of repeated antigenic stimulation on HIV viral load, resistance development, and the recovery of specific humoral and cellular immune responses in this patient population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on varicella vaccine (Hospital Clínic de Barcelona).